IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.
A new transiently induced region (interferon-λ 4 protein; IFNL4) harbouring a dinucleotide variant ss469415590 (TT or ΔG), upstream of IFNL3 (IL28B), was recently found to be associated with hepatitis C virus (HCV) clearance. To determine the effect of IFLN4 ss469415590 variation on the HCV response to IFN-based therapy in HCV/HIV-1 coinfected patients, ss469415590 was genotyped in a cohort of 207 patients from our clinic. Treatment failure occurred in 77% of minor ΔG-allele carriers versus 48% of noncarriers, indicating that the ΔG allele was strongly associated with treatment failure. Importantly, multivariate logistic analysis revealed that ss469415590 genotype was a better predictor of treatment failure than rs12979860.
aFundació irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona (UAB), Badalona bFundació de la Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Sandra
S
Franco
Ester
E
Aparicio
Mariona
M
Parera
Bonaventura
B
Clotet
Cristina
C
Tural
Miguel Angel
MA
Martinez
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D060085:Coinfection / Q000188:drug therapy; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D015658:HIV Infections / Q000150:complications*; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007378:Interleukins / Q000235:genetics*; D008297:Male; D011110:Polymorphism, Genetic; D012254:Ribavirin / Q000627:therapeutic use*; D017211:Treatment Failure; D000095022:Interferon Lambda
D000998:Antiviral Agents; D016898:Interferon-alpha; D007378:Interleukins; D012254:Ribavirin; C579163:IFNL4 protein, human; D000095022:Interferon Lambda